These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20173793)

  • 1. Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety.
    Ripaldi M; Parasole R; De Simone G; D'Amico MR; Migliorati R; Zanotta G; Loffredo G; Petruzziello F; Poggi V
    Bone Marrow Transplant; 2010 Nov; 45(11):1663-4. PubMed ID: 20173793
    [No Abstract]   [Full Text] [Related]  

  • 2. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy.
    Med Lett Drugs Ther; 2004 Mar; 46(1179):27-8. PubMed ID: 15057189
    [No Abstract]   [Full Text] [Related]  

  • 5. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann C; Herrstedt J
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):137-48. PubMed ID: 20131990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
    Hamadani M; Awab A; Chaudhary L; Tfayli A
    J Oncol Pharm Pract; 2006 Jun; 12(2):67-8. PubMed ID: 16984743
    [No Abstract]   [Full Text] [Related]  

  • 8. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.
    Sepúlveda-Vildósola AC; Betanzos-Cabrera Y; Lastiri GG; Rivera-Márquez H; Villasis-Keever MA; Del Angel VW; Díaz FC; López-Aguilar E
    Arch Med Res; 2008 Aug; 39(6):601-6. PubMed ID: 18662592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients.
    Aapro MS; Macciocchi A; Gridelli C
    J Support Oncol; 2005; 3(5):369-74. PubMed ID: 16218261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of palonosetron on postoperative nausea and vomiting in children following dental rehabilitation under general anesthesia.
    Yildirim MD; Cantekin K
    Pediatr Dent; 2014; 36(1):7E-11E. PubMed ID: 24717698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palonosetron (Helsinn).
    Stacher G
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1502-7. PubMed ID: 12431027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
    Kaushal J; Gupta MC; Kaushal V; Bhutani G; Dhankar R; Atri R; Verma S
    Singapore Med J; 2010 Nov; 51(11):871-5. PubMed ID: 21140114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
    Saito M; Tsukuda M
    Expert Opin Pharmacother; 2010 Apr; 11(6):1003-14. PubMed ID: 20307224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
    Rzepecki P; Pielichowski W; Oborska S; Barzal J; Mlot B
    Transplant Proc; 2009 Oct; 41(8):3247-9. PubMed ID: 19857722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical role of palonosetron for patients receiving cisplatin-based chemotherapy].
    Labianca R; Mandalà M; Clerici M
    Tumori; 2008; 94(2):suppl 23-5. PubMed ID: 18564622
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-acting serotonin antagonist (Palonosetron) and the NK-1 receptor antagonists: does extended duration of action improve efficacy?
    Melton MS; Nielsen KC; Tucker M; Klein SM; Gan TJ
    Anesthesiol Clin; 2014 Jun; 32(2):505-16. PubMed ID: 24882134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palonosetron: more than just another option?
    Di Maio M; Perrone F
    Lancet Oncol; 2009 Feb; 10(2):100-1. PubMed ID: 19185827
    [No Abstract]   [Full Text] [Related]  

  • 20. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update.
    Patel P; Robinson PD; Thackray J; Flank J; Holdsworth MT; Gibson P; Orsey A; Portwine C; Freedman J; Madden JR; Phillips R; Sung L; Dupuis LL
    Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28453189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.